MétaCan
Menu
← Back to cohort

Bladder cancer research funding in Canada and the United States: A comparison between stakeholder priorities and resource allocation from 2017 to 2019.

2021· article· en· W3134708025 on OpenAlexaffabout
Jeenan Kaiser, Ishjot Litt, Angela B. Smith, Bimal Bhindi, Nimira Alimohamed

Bibliographic record

VenueJournal of Clinical Oncology · 2021
Typearticle
Languageen
FieldMedicine
TopicBladder and Urothelial Cancer Treatments
Canadian institutionsPrincess Margaret Cancer CentreBaker Hughes (Canada)University of CalgaryUniversity of Alberta
Fundersnot available
KeywordsStakeholderBladder cancerAgency (philosophy)Funding AgencyMedicineGrant fundingBusinessCancerPublic relationsPolitical sciencePublic administrationSociologyInternal medicine

Abstract

fetched live from OpenAlex

422 Background: There is an increasing emphasis on patient-centered research to encourage cancer care that is responsive to patients' needs. Previously, the Bladder Cancer Advocacy Network (BCAN) Patient Survey Network (PSN) engaged patients and other key stakeholders and compiled a prioritized list of research questions in bladder cancer. However, it is uncertain whether these priorities have successfully guided subsequent resource allocation by funding agencies. The purpose of this study was to understand how bladder cancer research funding has been allocated in recent years and to determine whether funding patterns have aligned with patient and caregiver priorities. Methods: We investigated publicly available research databases online or contacted agencies directly to determine bladder cancer research fund allocation in Canada and the US from 2017 to 2019. Each funding competition and all funded projects were evaluated to assess whether they aligned with previously identified priority research areas. Trends in funding allocation were assessed and several key variables including country, year, agency focus, cancer stage, and funding amount were analyzed. Results: Fifteen agencies provided funding to bladder cancer research between 2017 and 2019, amounting to a total of $78,525,974 in funding for 298 projects across Canada and the US. Of this funding, $23,268,258 (30%) went towards projects addressing the stakeholder-identified high priority research questions, $15,575,064 (20%) went towards projects addressing lesser priority questions, and the remaining $39,682,652 (50%) funded projects addressing questions which did not align with previously identified stakeholder priorities. General agencies (non-bladder cancer-specific) funded more priority (high and lesser) projects than bladder cancer-specific agencies (p < 0.001). Among projects addressing non-muscle invasive bladder cancer, 36% of funding went to high priority areas, compared to 13% and 27% for muscle-invasive bladder cancer and metastatic bladder cancer, respectively. Among the top 10% of projects (n = 30) with the greatest funding amount (combined $43,249,792), 45% of the funding went to high priority areas, 21% went to lesser priority areas, and 34% went to non-priority areas. Conclusions: Of nearly $80,000,000 USD allocated to bladder cancer research in recent years, approximately half was allocated to projects addressing stakeholder-identified priority areas while half was allocated to projects that were not aligned with stakeholder priorities. More work is needed to ensure stronger alignment between stakeholder-identified priority areas and funding allocation in bladder cancer research.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.013
metaresearch head score (Gemma)0.040
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Incentives · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.987
Threshold uncertainty score0.842

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0130.040
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0060.014
Science and technology studies0.0040.002
Scholarly communication0.0050.002
Open science0.0020.005
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.393
GPT teacher head0.520
Teacher spread0.127 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designObservational
DomainIncentives
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicBladder and Urothelial Cancer Treatments→French-language works237,207→